



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 348 564
A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88305904.0

(51) Int. Cl.4: C07K 5/00 , A61K 37/02

(22) Date of filing: 29.06.88

(30) Priority: 01.07.88 US 68509

(43) Date of publication of application:
03.01.90 Bulletin 90/01

(84) Designated Contracting States:
ES GR


(71) Applicant: SCHERING CORPORATION
2000 Galloping Hill Road
Kenilworth New Jersey 07033(US)

(72) Inventor: Nagabhushan, Tattanahalli L.
3 Sunset Lane
Parsippany New Jersey 07054(US)
Inventor: Haslanger, Martin F.
53 W. Glen Avenue
Ridgewood New Jersey 07540(US)
Inventor: Czarniecki, Michael F.
538 Fairmont Avenue
Westfield New Jersey 07090(US)

(74) Representative: Ritter, Stephen David et al
Mathys & Squire 10 Fleet Street
London EC4Y 1AY(GB)

(54) Orally active antiandrogens.

(57) Antiandrogenic poly-peptidyl esters, represented by the formula



EP 0 348 564 A1

pharmaceutical compositions comprising same, methods of manufacture, uses and intermediates are disclosed.


ORALLY ACTIVE ANTIANDROGENS

Flutamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (previously known as 4'-nitro-3'-trifluoromethylisobutyranilide), and related substituted N-phenylamides are known antiandrogens, effective in the treatment of prostatic carcinoma, benign prostatic hypertrophy, acne and hirsutism. See U.S. Patents 4,329,364; 3,995,060; 4,139,638; and 4,161,540, all to Neri et al.

Also known as antiandrogens are hydroxy- and alkanoyloxy-substituted N-phenylamides such as 2-hydroxy-2-methyl-N-[(4-substituted and 3,4-disubstituted)phenyl]propanamides. See Gold, U.S. Patent 3,875,229, wherein 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide is indicated to be a preferred species. Said compound has been identified as the major active metabolite of flutamide. See Katchen et al, *J. Clin. Endocrin. and Metab.*, 41 (1975), p. 373-9.

Other related antiandrogens include N-phenylalkanamides containing a cyano substituent on the phenyl ring (see U.S. Patent 4,239,776 to Glen et al), (N-phenyl)phenylalkanamides (see U.S. Patent 4,386,080 to Cressley et al), (N-phenyl)heterocyclalkanamides (see U.S. Patent 4,535,092 to Hughes), and (N-phenyl)-phenylsulfonylalkanamides (see U.S. Patent 4,636,505 to Tucker).

The compounds of this invention are represented by the formula



wherein

X is CN, NO₂, CF₃, Cl, Br or I;

Y is F, Cl, Br, I, NO₂, NH₂, CF₃ or CN;

R is H or lower alkyl;

R¹ and R² are independently straight or branched alkyl radicals having up to eight carbon atoms, or R¹ and R² together with the carbon to which they are attached form a cyclopropyl or cyclobutyl ring, or one of R¹

and R² is alkyl as defined above and the other is aryl, arylalkyl or aryl-S(O)₀₋₂alkyl, wherein the aryl group may be substituted by 1-3 substituents selected from the group consisting of H, halogen, NO₂, CO₂H, CONH₂, CN, lower alkyl, alkoxy, alkanoyl, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, perfluoro lower alkylsulfinyl, perfluoro lower alkylsulfonyl, alkoxy-carbonyl, phenyl, phenylthio, phenylsulfinyl and phenylsulfonyl;


R³ is a poly-peptide group, which peptidyl group is joined to the molecule by a C-terminal amino acid residue; and the isomers and pharmaceutically acceptable salts thereof.

The present invention relates to novel peptidyl esters of 2-hydroxy-N-phenylalkanamide derivatives useful as antiandrogenic agents for the treatment of prostatic carcinoma, benign prostatic hypertrophy, hirsutism, acne and related disorders.

The invention also relates to a method of treating androgen-dependent disease conditions comprising administering to a mammal, in particular to a human, in need of such treatment an antiandrogenic effective amount of a peptidyl ester of a 2-hydroxy-N-phenylalkanamide derivative.

Another aspect of the invention relates to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically acceptable carrier.

The present invention also relates to a method of producing a compound of formula I wherein X, Y, R, R¹, R² and R³ are as defined above, characterized by contacting a compound of formula II



wherein Z is OH or a C-terminal amino acid residue, with a peptidyl group of the formula R³H, optionally including amino protecting groups on the compound of formula II and/or the peptidyl group R³H, followed by removal of the protecting groups if necessary.

In particular, the invention relates to tri-peptidyl esters of 2-hydroxy-N-phenylalkanamide derivatives, wherein the preferred derivative is 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl] propanamide.

As used herein, the term "polypeptidyl" refers to a peptide moiety comprising at least two amino acid groups. R³ preferably is a di-, tri- or tetrapeptidyl group consisting of 2, 3 or 4 amino acids, which acids are preferably selected from naturally occurring amino acids. As used herein the term "C-terminal amino acid residue" refers to an amino acid radical ending in a COO⁻ group. "Lower alkyl" refers to straight or branched chain alkyl groups having 1 to 4 carbon atoms. Similarly, the term "alkoxy" and "alkanoyl" refer to groups having chain lengths of 1-4 carbon atoms. The term "perfluoro lower alkyl" refers to alkyl groups in which at least one of the carbon atoms is totally fluorinated, e.g. trifluoromethyl, α,α -difluoroethyl and β,β,β -trifluoroethyl. "Aryl" refers to phenyl or naphthyl rings.

The di-, tri- or tetra-peptidyl groups are comprised of naturally occurring amino acids joined to each other by conventional peptide (i.e., -CONH-) bonds and joined to the rest of the molecule through a C-terminal amino acid residue, i.e. a -COO⁻ group. Examples of naturally occurring amino acids are proline, sarcosine (N-methylglycine), alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine.

Preferred compounds of formula I are those wherein Y is trifluoromethyl and X is nitro, iodo, bromo, chloro or cyano, with nitro and cyano being more preferred. Another group of preferred compounds are those wherein X is nitro and Y is bromo or chloro. A third group of preferred compounds are those wherein R is hydrogen. Still another group of preferred compounds are those wherein R¹ and R² are each methyl. A further group of preferred compounds are those wherein R¹ is methyl and R² is aryl-S(O)₀₋₂alkyl, especially wherein R² is 4-fluorophenylsulfonylmethyl. Especially preferred are compounds of formula I wherein R is hydrogen, X is nitro, Y is trifluoromethyl, and R¹ and R² are each methyl. Also, especially preferred are compounds wherein R is hydrogen, X is cyano, Y is trifluoromethyl, R¹ is methyl and R² is 4-fluorophenylsulfonylmethyl.

For R³, tri-peptidyl esters are preferred. Preferred amino acids are lysine, glycine, proline, alanine and sarcosine. Preferred tri-peptide groups are alanyl-glycyl-sarcosyl, lysyl-glycyl-sarcosyl, and lysyl-glycyl-prolyl, with the first being more preferred.

Preferred compounds of the invention are:


L-lysyl-glycyl-N-methylglycine, [1-methyl-[[4-nitro-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester; L-alanyl-glycyl-N-methylglycine, [1-methyl-[[4-nitro-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester; and L-lysyl-glycyl-L-proline, [1-methyl-[[4-nitro-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester. Also preferred are the corresponding peptidyl esters of 2-hydroxy-2-methyl-3-(4-fluorophenylsulphonyl)-N-[4-cyano-3-(trifluoromethyl)phenyl]propanamide, i.e.;

L-lysyl-glycyl-N-methylglycine, [1-(4-fluorophenylsulfonylmethyl)-1-methyl-[[4-cyano-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester; L-alanyl-glycyl-N-methylglycine, [1-(4-fluorophenylsulfonylmethyl)-1-methyl-[[4-cyano-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester; and L-lysyl-glycyl-L-proline, [1-(4-fluorophenylsulfonylmethyl)-1-methyl-[[4-cyano-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester.

Compounds of this invention may form acid addition salts with pharmaceutically acceptable acids such as hydrochloric, hydrobromic, methane sulfonic, toluenesulfonic and sulfuric acids.

Compounds of this invention may possess one or more asymmetric carbon atoms, e.g. in compounds wherein R¹ and R² are different, and in compounds wherein one or more of the amino acids comprising R³ contain a chiral center. The stereoisomers can be separated by methods known in the art. Preferably, when specific isomerism is desired in the product, stereospecific starting materials are used. All stereoisomers are contemplated as a part of this invention. Preferred for R³ are amino acids in the L-configuration.

Compounds of the invention are prepared by methods well known in the art. A preferred starting material is a compound of formula II



wherein X, Y, R, R¹ and R² are as defined above and Z is OH or a C-terminal amino acid residue. When Z is OH, the compound of formula II is reacted with the carboxy group of an N-protected amino acid, then one or more amino acids are added by conventional peptide condensation reactions to obtain the peptidyl ester. When Z is an amino acid residue, additional amino acids or peptides are similarly added by condensation reactions. Alternatively, the C-terminal group of a di-, tri- or tetra-peptidyl group may be directly reacted with a compound of formula II wherein Z is OH. The reaction of a compound of formula II wherein Z is OH with the carboxy group of an N-protected amino acid is carried out at 0-25° C in an inert solvent such as dichloromethane in the presence of a base such as 4-N,N-dimethylaminopyridine and a condensing agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (DEC). The subsequent addition of an amino acid or a peptide is similarly carried out at 0-25° C in an inert solvent such as dimethylformamide in the presence of a base such as triethylamine and condensing agents such as DEC and 1-hydroxybenzotriazole (HOBt). Those skilled in the art will recognize that many other reactions known in peptide synthesis can also be employed.

The known coupling methods include amino group protection during the coupling reaction, for example with a protecting group such as N-t-butoxycarbonyl (BOC), followed by removal of the protecting group to yield compounds of formula I.

Starting materials of formula II are known (See U.S. 3,875,229 and U.S. 4,636,505 cited above). Amino acids and di-, tri- and tetra- peptides are known or may be prepared by well known methods.

Following is an example of a preparation of a tri-peptidyl ester of formula I. Those skilled in the art will recognize that by modifying this procedure, e.g. by using different amino acids or by increasing or decreasing the number of amino acids, other compounds of formula I may be prepared.

Example

L-LYSYL-GLYCYL-L-PROLINE-[1-METHYL-[[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]-AMINOCARBONYL]ETHYL]ESTER, DIHYDROCHLORIDE

A. Bis-N_α,N_ε-t-BOC-L-lysine succinimidyl ester:

Dissolve bis-N_α,N_ε-t-BOC-L-lysine (6.2g), N-hydroxysuccinimide (2.8g) and N,N-dicyclohexylcarbodiimide (5.1g) in 1,2 dimethoxyethane (20ml) and stir at 0° C for 12 hr. Filter the reaction mixture and evaporate the filtrate to dryness. Stir residual oil at 0° with ether and filter to obtain the title compound as a crystalline product (8.2g).

B. (Bis-N_α,N_ε-t-BOC-L-Lysyl)glycine:

Dissolve the product of Step A (4.4g) in dimethylformamide (DMF)(32ml) and add to a solution of glycine (0.75g) and sodium bicarbonate (1.7g) in water (24 ml). Stir at 0° C for 2 hours and then at room temperature for 12 hours. Remove the solvent in vacuo and dissolve the residue in water. Adjust the pH to 3.5 using aqueous hydrochloric acid and extract the resultant solution with ethyl acetate. Wash the ethyl acetate with water and saturated brine solution and dry with sodium sulfate. Evaporate the ethyl acetate to obtain the title compound (3.5 g). Calculated for C₁₈H₃₃N₃O₇: C=53.53%; H=8.17%; N=10.41%. Found: C=53.16%; H=8.43%; N=10.70%.

C. (N-t-BOC-L-Proline)-[1-methyl-[[4-nitro-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl]ester:

Dissolve 1-methyl-[(4-nitro-3-trifluoromethyl)phenyl]aminocarbonyl]ethanol (3.5g), N-t-BOC-L-proline (2.6g), 4-dimethylaminopyridine (0.70 g) and DEC (2.1 g) in dichloromethane (120 ml). Stir at 0° C for 2 hours, then for 5 days at room temperature. Evaporate the solvent, dissolve the resultant residue in ethyl acetate and wash the ethyl acetate successively with saturated sodium bicarbonate, water, and saturated
 5 brine solution. Dry the ethyl acetate with sodium sulfate and evaporate to a syrup. Chromatograph the product on silica gel, eluting with dichloromethane:ethyl acetate (99:1) to obtain the title compound (4.2 g). Calculated for $C_{21}H_{26}N_3O_7F_3$: C = 51.53%; H = 5.35%; N = 8.58%. Found: C = 51.63%; H = 5.28%; N = 8.31%.

10

D. L-Proline-[1-methyl-[(4-nitro-3-trifluoromethyl)phenyl]aminocarbonyl]ethyl]ester, hydrochloride:

Dissolve the product of Step C (3.6 g) in dioxane (10 ml), cool to 0° and add 35 ml of saturated HCl in dioxane. Stir at 0° for 1 hour and then at room temperature for 1 hour. Evaporate the solvent, add ethyl
 15 ether and stir at 0° for 12 hours. Filter the solid to obtain the title compound (2.8 g). Calculated for $C_{16}H_{19}N_3O_5ClF_3$: C = 45.13%; H = 4.49%; N = 9.87%. Found: C = 45.56%; H = 4.80%; N = 9.41%.

20

E. (Bis- N_{α},N_{ϵ} -t-BOC-L-lysyl)-glycyl-proline-[1-methyl-[(4-nitro-3-trifluoromethyl)phenyl] aminocarbonyl] ethyl]ester:

Dissolve the product of Step B (1.6 g) and the product of Step D (1.5 g) in DMF (35 ml), add HOBT (0.65 g), DEC (1.2 g) and triethylamine (1.3 ml). Stir at 0° for 12 hours. Evaporate the solvent in vacuo and
 25 dissolve the resultant residue in ethyl acetate. Wash the ethyl acetate successively with 10% aqueous citric acid, water, saturated sodium bicarbonate solution, water and saturated brine solution. Dry the ethyl acetate with sodium sulfate and evaporate the solvent to obtain the title compound (2.4 g). Calculated for $C_{34}H_{49}N_6O_{11}F_3$: C = 52.70%; H = 6.37%; N = 10.84%. Found: C = 52.66%; H = 6.43%; N = 10.43%.

F. Dissolve the product of Step E (2.1 g) in dioxane (5 ml) at 0° C and add saturated HCl in dioxane (45 ml). Stir for 1 hour at 0° C, add additional saturated HCl in dioxane (20 ml) and stir for 1 hour at room
 30 temperature. Evaporate the dioxane in vacuo and triturate the resultant residue with ether. Filter the solid to obtain the title compound (1.6 g). Calculated for $C_{24}H_{35}N_6O_7Cl_2F_3$: C = 44.51%; H = 5.44%; N = 12.98%. Found: C = 44.90%; H = 5.75%; N = 12.49%.

The antiandrogenic activity of flutamide and its active metabolite are well documented. However, we have surprisingly found that the peptidyl esters of this invention demonstrate superior bioavailability
 35 compared to flutamide, its active metabolite, or to simple esters of the active metabolite, e.g. 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide acetate (hereinafter acetyl flutamide).

The following Table 1 shows that all amino acid esters tested, especially the tri-peptidyl esters, delivered the active metabolite of flutamide more efficiently than either the active metabolite itself or simple
 40 esters of the active metabolite.

Plasma concentrations of the flutamide active metabolite in 300-350 gram male Sprague Dawley rats following single oral 5 mg/kg doses of the compounds listed were determined by gas-liquid chromatog-
 45 raphy. Areas under the 0-4 hour plasma level curves were calculated for each compound and compared to the area obtained for flutamide active metabolite as shown in the last column of the table.

50


55

Table 1

Plasma Concentrations (ng/ml)^a of Flutamide Active Metabolite in Rats After Administration of Various Esters Thereof

Compound

Concentration



Chemical structure of the flutamide active metabolite: A benzene ring substituted with a nitro group (O_2N) at position 1, a trifluoromethyl group (F_3C) at position 3, and an amide group ($-\text{NH}-\text{C}(=\text{O})-\text{C}(\text{CH}_3)_2-\text{R}$) at position 4.

<u>R</u>	<u>2 Hours</u>	<u>4 Hours</u>	<u>0-4 Hours</u>	<u>Relative Rank</u>
H (flutamide)	715	974	2404	1.00
OH (metabolite)	183 ^b	810	1176	0.49
OAc	142	278	562	0.23
ala-gly-sar	1952	1115	5019	2.09
lys-gly-sar	1103	1248	3454	1.44
pro	1059	1393	3511	1.46
sar	1345	958	3648	1.52
lys-gly-pro	2277	1847	6401	2.66

^a All concentrations are average of 2 animals and normalized to a 5 mg/kg dose of flutamide active metabolite except as noted.

^b Value from one animal

Using a similar method, the plasma concentrations of flutamide active metabolite after administration of the two most active peptidyl esters from Table 1 and flutamide itself were determined over a period of sixteen hours, as shown in Table 2.

Table 2

Plasma Concentrations (ng/ml) ^a of Flutamide Active Metabolite for up to 16 Hours								
Ester	0.5 hr	1 hr	2 hr	4 hr	8 hr	16 hr	0-16 hr	Relative Rank
- (flutamide)	210	322	614	722	649	236	8272	1.00
ala-gly-sar	1079	2029	1365	1803	1005	423	17240	2.08
lys-gly-pro	1392	1907	1751	1170	1054	256	15611	1.89

^a All concentrations are average of 3 animals and normalized to a 5 mg/kg dose of flutamide active metabolite.

For the treatment, i.e., the reduction or elimination of androgenic conditions in humans, in particular prostatic carcinoma, compounds of this invention should be administered at a rate which provides a quantity of flutamide active metabolite equivalent to a dose of about 1 to 30 mg per kg of body weight per day, preferably about 2 to about 20 mg per kg of body weight per day. The aforementioned doses may be divided into two or more portions for administration over the course of the day, for example, one-third of the daily dose administered three times per day. Pharmaceutical preparations for a 70 kilogram mammal should provide a daily dose of flutamide active metabolite of about 100 mg to about 2000 mg, preferably about 250 mg to about 1500 mg, and more preferably about 500 mg to about 1000 mg, and should be continued until symptomatic relief is obtained, as ascertained by the attending diagnostician.

The pharmaceutical preparations of this invention include such oral dosage forms as tablets, capsules

and elixirs as well as parenteral dosage forms, e.g. ampuls and vials. Additionally, they may be in the form of suppositories (both rectal and urethral). In tablet form, a compound of this invention is compounded with an inert pharmaceutical carrier which may contain a suitable binder, such as gums, starches, and sugars. The ingredients may also be incorporated into gelatin capsules or formulated into elixirs which have the advantage of being susceptible to manipulations in flavor by the addition of standard natural or synthetic flavoring agents. Highly satisfactory administration may also be achieved in the form of aqueous parenteral suspension.

Preferably, the aforementioned formulations are so proportioned as to afford a unit dose of about 125 or about 250 mg of flutamide active metabolite. Thus, for example, a preferred dosage of 750 mg per day could thus be administered as one 250 mg tablet or capsule three times per day or two 125 mg tablets or capsules three times per day.

Representative formulations for compounds of this invention are as follows, wherein "Drug" refers to a peptide ester of flutamide active metabolite:

TABLET FORMULATION

Ingredients	Milligrams per Tablet
Drug	250.00
Lactose, anhydrous	221.70
Sodium lauryl sulfate	15.00
Microcrystalline cellulose	100.00
Starch	162.50
Water	0.29*
Silica Gel (Syloid-244)	0.40
Magnesium stearate	0.40
Tablet Weight	750.00

*evaporates.

Blend the above ingredients using a wet granulation method and compress into tablets using standard techniques.

PARENTERAL SUSPENSION FORMULATION

Ingredients	Milligrams per Milliliter
Drug	250.00
Methyl Cellulose 15 cps. U.S.P.	0.25
Sodium Citrate, Dihydrate	30.00
Benzyl Alcohol, NF	9.00
Methylparaben, U.S.P.	1.80
Propylparaben, U.S.P.	1.20
Water for Injection, U.S.P. q.s.a.d.	1.00

Using standard techniques, combine the above ingredients to prepare a parenteral suspension.

CAPSULE FORMATION


Milligrams/Capsule			
Ingredients			
Drug	125 mg	250 mg	200 mg
Lactose, hydrous, USP	360.5	235.5	185
Sodium Lauryl Sulfate, NF	12	12	12
Povidone, USP (Polyvinylpyrrolidone)	25	25	25
Water, Purified, USP (evap.) or S.D. Alcohol, 3-A (evap.)*			
Corn Starch (Food Grade)	77	77	77
Magnesium Stearate, NF	0.5	0.5	1.0
Full Weight (mg.)	600	600	500

*Approximately 75 ml. 3-A alcohol/100 capsules, or 60 ml. water/1000 capsules.

Blend the above ingredients and fill capsules using standard techniques.

Claims

1. A compound represented by the formula



wherein

X is CN, NO₂, CF₃, Cl, Br or I;

Y is F, Cl, Br, I, NO₂, NH₂, CF₃ or CN;

R is H or lower alkyl;

R¹ and R² are independently straight or branched alkyl radicals having up to eight carbon atoms, or R¹ and R² together with the carbon to which they are attached form a cyclopropyl or cyclobutyl ring, or one of R¹ and R² is alkyl as defined above and the other is aryl, arylalkyl or aryl-S(O)₀₋₂alkyl, wherein the aryl group may be substituted by 1-3 substituents selected from the group consisting of H, halogen, NO₂, CO₂H, CONH₂, CN, lower alkyl, alkoxy, alkanoyl, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, perfluoro lower alkylsulfinyl, perfluoro lower alkylsulfonyl, alkoxycarbonyl, phenyl, phenylthio, phenylsulfinyl and phenylsulfonyl;

R³ is a poly-peptidyl group, which peptidyl group is joined to the molecule by a C-terminal amino acid residue; and the isomers and pharmaceutically acceptable salts thereof.

2. A compound as defined in claim 1 wherein R³ is a di-, tri-, or tetra-peptidyl group wherein the amino acids present in the peptidyl group are naturally occurring amino acids.

3. A compound as defined in claim 1 or claim 2 wherein R is hydrogen.

4. A compound as defined in any of claims 1-3 wherein X is nitro, iodo, bromo, chloro or cyano.

5. A compound as defined in any of claims 1-4 above wherein Y is trifluoromethyl.

6. A compound as defined in any of claims 1-5 above wherein R³ is a tri-peptidyl group.

7. A compound as defined in any of claims 1-6 above wherein R¹ and R² are each methyl.

8. A compound as defined in any of claims 1-6 above wherein R¹ is methyl and R² is 4-fluorophenylsulfonylmethyl.

9. A compound as defined in any of claims 1-8 above wherein the tri-peptidyl group is selected from alanyl-glycyl-sarcosyl, lysyl-glycyl-sarcosyl and lysyl-glycyl-prolyl.

10. A compound of claim 1 which is:

L-lysyl-glycyl-N-methylglycine, [1-methyl-[[4-nitro-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester;

L-alanyl-glycyl-N-methylglycine, [1-methyl-[[4-nitro-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl] ester;


L-lysyl-glycyl-L-proline, [1-methyl-[[4-nitro-3-(trifluoromethyl)phenyl]aminocarbonyl]ethyl]ester;
 L-lysyl-glycyl-N-methylglycine, [1-(4-fluorophenylsulfonylmethyl)-1-methyl-[[4-cyano-3-trifluoromethyl)-
 phenyl]aminocarbonyl]ethyl]ester;
 L-alanyl-glycyl-N-methylglycine, [1-(4-fluorophenylsulfonylmethyl)-1-methyl-[[4-cyano-3-trifluoromethyl)-
 phenyl]aminocarbonyl]ethyl]ester; or
 L-lysyl-glycyl-L-proline, [1-(4-fluorophenylsulfonylmethyl)-1-methyl-[[4-cyano-3-trifluoromethyl)phenyl]-
 aminocarbonyl]ethyl]ester.

11. The use of a composition as defined in any one of claims 1-10 for the preparation of a pharmaceutical composition useful in the treatment of androgen dependent disease.

12. The use of claim 11 wherein the androgen dependent disease state is prostatic carcinoma.

13. A pharmaceutical composition comprising a compound as defined in any one of claims 1-10 in combination with a pharmaceutically acceptable carrier.

14. A method of producing a compound of claim 1 wherein X, Y, R, R¹, R² and R³ are as defined in claim 1 characterized by contacting a compound of formula II



wherein Z is OH or a C-terminal amino acid residue with a peptidyl group of the formula R³H, optionally including amino protecting groups on the compound of formula II and/or the peptidyl group R³H, followed by removal of the protecting groups if necessary.

15. A method for making a pharmaceutical composition comprising mixing a compound of claim 1 with a pharmaceutically acceptable carrier.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 30 5904

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	EP-A-0 056 210 (PHARMINDUSTRIE) * Whole document * & WO-A-82 002 382 ---	1,11	C 07 K 5/00 A 61 K 37/02
A	US-A-4 154 727 (HIRAI et al.) * Title page, columns 17,18 * ---	1,11	
A	CH-A- 641 761 (PENTAPHARM) * Whole document * -----	1,11	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 07 K A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 16-06-1989	Examiner RAJIC M.
<div>CATEGORY OF CITED DOCUMENTS</div> <div>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</div> <div>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document</div>			

EPO FORM 1503 03.82 (P0401)